Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13041699 | 0.88 | CNR2 (0.38) | KMT2AMEN1HDAC1HDAC8 | |
| SCHEMBL13041706 | 0.82 | RAB9A (0.39) | RAB9AHDAC1HDAC8 | |
| SCHEMBL3729186 | 0.81 | POLB (0.41) | RAB9ASMN1; SMN2TP53NPC1POLB | |
| SCHEMBL3729573 | 0.80 | RAB9A (0.42) | RAB9ASMN1; SMN2TP53NPC1POLB | |
| SCHEMBL13041654 | 0.78 | TSHR (0.48) | POLBMAPK1HDAC1 | |
| SCHEMBL3746499 | 0.75 | HDAC1 (0.41) | RAB9ASMN1; SMN2TP53NPC1POLB | |
| SCHEMBL3734568 | 0.73 | GRM2 (0.46) | HDAC1HDAC8 | |
| SCHEMBL13099529 | 0.73 | CNR2 (0.41) | — | |
| SCHEMBL13099557 | 0.72 | CNR2 (0.50) | — | |
| SCHEMBL9978109 | 0.71 | SMN1; SMN2 (0.37) | RAB9ASMN1; SMN2TP53NPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100278835-A1 | NOVEL COMPOUNDS 660 | ASTRAZENECA UK LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100278835-A1 | NOVEL COMPOUNDS 660 | RB1, RPP30, SARS1 | RAB9A 58/4885SMN1; SMN2 48/4885TP53 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.